Response to "Intrathecal trastuzumab: What else do we need to consider?" by Gao et al
Neuro Oncol
.
2023 Feb 14;25(2):420-421.
doi: 10.1093/neuonc/noac258.
Authors
Émilie Le Rhun
1
,
Florence Oberkampf
2
,
Claire Bonneau
3
4
Affiliations
1
Departments of Neurology and Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
2
Hemato-oncology Unit, Alpes-Leman Hospital (CHAL), Contamine-sur-Arve, France.
3
Department of Surgery, Institut Curie-St Cloud, Saint Cloud, France.
4
INSERM U900, Institut Curie-St Cloud, Saint Cloud, France.
PMID:
36534958
PMCID:
PMC9925668
DOI:
10.1093/neuonc/noac258
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized*
Humans
Receptor, ErbB-2*
Trastuzumab / therapeutic use
Substances
Trastuzumab
Receptor, ErbB-2
Antibodies, Monoclonal, Humanized